Translate the text from Welsh to English.



 
Heddiw mae'r Cyd\-bwyllgor ar Imiwneiddio a Brechu, fel rhan o'r adolygiad diwethaf a gynhaliwyd ganddo o'r rhaglen brechu rhag COVID\-19, wedi cyhoeddi datganiad yn argymell dos ychwanegol o frechiad atgyfnerthu'r gwanwyn ar gyfer ein dinasyddion mwyaf agored i niwed.


Prif nod y rhaglen brechu rhag COVID\-19 o hyd yw sicrhau nad yw pobl yn datblygu salwch difrifol (gan arwain at fynd i'r ysbyty a marwolaethau) sy'n codi o COVID\-19\. Mae pobl hŷn, pobl sy'n byw mewn cartrefi gofal i oedolion hŷn a phobl sy'n imiwnoataliedig yn parhau i wynebu'r risg uchaf o ddatblygu salwch difrifol yn sgil COVID\-19\. Mae'r Cyd\-bwyllgor wedi argymell, fel strategaeth ragofalus, y dylai'r bobl ganlynol gael ail ddos o'r brechiad atgyfnerthu:


* **oedolion 75 oed a throsodd;**
* **pobl sy’n byw mewn cartref gofal i oedolion hŷn, ac**
* **unigolion 5 oed a throsodd sy'n imiwnoataliedig (fel y'i diffinnir yn nhabl 3 neu 4 yn y** **Llyfr Gwyrdd****(Saesneg yn Unig))**


Wrth wneud yr argymhelliad hwn, ystyriodd y Cyd\-bwyllgor y data sydd ar gael o'r DU a gweddill y byd sy'n awgrymu bod imiwnedd pobl hŷn yn fwy tebygol o fynd yn wannach o ganlyniad i'r ffaith nad yw eu system imiwnedd yn gallu ymateb yn effeithiol i heintiau nac i frechlynnau i'r un graddau, a'u bod yn fwy tebygol o lawer o gael salwch difrifol os cânt eu heintio. Yn ymarferol, am eu bod wedi cael eu blaenoriaethu ar gyfer brechiadau ar ddechrau rhaglen brechu rhag COVID\-19 yr hydref a ddechreuodd ym mis Medi 2022, mae rhagor o amser wedi mynd heibio ers i bobl hŷn gael eu dos diweddaraf o'r brechlyn.


Mae'r Cyd\-bwyllgor hefyd wedi nodi yn ystod y rhaglen hon, fod modd defnyddio brechlyn COVID\-19 VidPrevtyn Beta a gafodd ei ddatblygu gan Sanofi/GSK a'i gymeradwyo gan yr Asiantaeth Rheoleiddio Meddyginiaethau a Chynhyrchion Gofal Iechyd (MHRA) ym mis Rhagfyr, ochr yn ochr â'r brechlynnau mRNA diweddaraf a ddatblygwyd gan Pfizer a Moderna. Mewn treialon clinigol, roedd canlyniadau brechlyn Sanofi/GSK yn gymaradwy â chanlyniadau’r brechlynnau mRNA COVID\-19\. Mae'r Cyd\-bwyllgor wedi argymell y brechlyn ar gyfer pobl dros 75 oed, ac mae’n addas i bobl nad ydynt yn gallu goddef brechlynnau mRNA. Nid oes angen sicrhau amodau storio mor llym ar gyfer y brechlyn hwn o'i gymharu â’r brechlynnau mRNA COVID\-19, sy'n golygu bod modd gweithredu mewn ffordd fwy hyblyg wrth ei ddefnyddio. Mae'n bosibl y bydd hyn yn ei gwneud yn haws i bobl gael eu brechu.


Rwyf wedi derbyn y cyngor hwn ac wedi gofyn i fyrddau iechyd gadarnhau'r cynlluniau y maent wedi bod yn eu llunio ers cryn amser. Caiff manylion y rhaglen eu nodi yng Nghylchlythyr Iechyd Cymru a gaiff ei gyhoeddi gan y Prif Swyddog Meddygol.


Ar sail y cyngor a gafwyd gan y Cyd\-bwyllgor, cyhoeddais yn ddiweddar ddiwedd y cynnig cyffredinol o'r brechiad atgyfnerthu gwreiddiol a oedd yn cael ei gynnig i bobl dros 5 oed o hydref 2021 ymlaen. Mae'r cynnig hwn yn dod i ben ar ddiwedd mis Mawrth, felly mae amser o hyd i unrhyw un nad yw wedi manteisio arno eto i gael ei frechu, a byddwn yn annog pobl i wneud hynny.


Fel arfer, rwy'n ddiolchgar iawn i'r GIG ac i bawb sy'n rhan o'r rhaglen frechu am eu gwaith caled parhaus.







Translation:


 
The Joint Committee on Vaccination and Immunisation (JCVI), as part of its latest review of the COVID\-19 vaccination programme, has today published a statement, which recommends an additional spring booster dose for our most vulnerable citizens.


The primary aim of the COVID\-19 vaccination programme continues to be the prevention of severe disease (hospitalisation and mortality) arising from COVID\-19\. Older people, residents in care homes for older adults, and those who are immunosuppressed continue to be at highest risk of severe COVID\-19\.  The Committee has recommended, as a precautionary strategy, a second booster dose in the spring for:


* **adults aged 75 years and over;**
* **residents in a care home for older adults, and**
* **individuals aged 5 years and over who are immunosuppressed (as defined in table 3 or 4 in the** **Green Book****)**


In making this recommendation they considered available data from the UK and internationally which suggests that older people are more likely to experience waning of immunity due to a decreased capacity of the immune system to respond effectively to infections or vaccines, and much more likely to experience severe disease if infected. Practically, because they were prioritised for vaccination at the start of the COVID\-19 Autumn booster programme that started in September 2022, older people are also now furthest in time from their last vaccine dose. 


The Committee has also advised that the VidPrevtyn Beta COVID\-19 vaccine developed by Sanofi/GSK and approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in December, can be deployed alongside the very latest mRNA vaccines by Pfizer and Moderna during this programme. In clinical trials the Sanofi/GSK vaccine had results comparable to the COVID\-19 mRNA vaccines and has been recommended by the JCVI for people over 75\.  This vaccine, which is suitable for those intolerant of mRNA vaccines, also has less stringent storage conditions, as compared to the mRNA COVID\-19 vaccines, which will allow for greater operational flexibility in its use and may improve access to vaccination.


I have accepted this advice and have asked health boards to firm up the plans they have been making for some time.  The details of the programme will be set out in a Welsh Health Circular issued by the Chief Medical Officer.


On the basis of advice received by the JCVI, I recently announced the end of the universal offer of the original booster that was offered to all those aged over 5 years from autumn 2021\.  This offer ends at the end of March, so there is still time for anyone that hasn’t taken it up to come forward for vaccination and I would urge people to do so.


As ever, I am extremely grateful to the NHS and everyone involved in the vaccination programme for their continued hard work.